Printer Friendly

Novavax receives important patent covering the production of viral vaccines in a proprietary cell line.

Novavax, Inc. (Columbia, MD; 301-854-3900) announced it has been granted United States Patent 6,025,182 "Method for Producing a Virus from an African Green Monkey Kidney Cell Line" developed by Louis Potash, PhD, director of the Novavax biomedical services division. This patent is the third in a series covering the use of African Green Monkey Kidney cells as a cell line to both isolate and grow human viral agents leading to the production of live and inactivated viral vaccines.

Dr. Potash stated, "This cell line, which is extremely sensitive and susceptible to a wide range of human pathogens including, but not restricted to, respiratory agents (Influenza viruses, Parainfluenza viruses, Respiratory Syncytial viruses), Polioviruses, Rotaviruses, Coxsackie viruses, Dengue viruses and Hepatitis A. Most importantly, African Green Monkey Kidney cells offer the researcher/investigator the luxury of having one cell line that can be used not only for isolation but also for the production of a potential viral vaccine, eliminating the need to adapt to another cell system. Furthermore, in a clinical/diagnostic setting, this cell line offers a significant advantage in contrast to primary monkey kidney cells, which are frequently contaminated with a number of cytopathic simian agents."

D. Craig Wright, MD, chief scientific officer of Novavax, added, "We are very excited that Dr. Potash's African Green Monkey Kidney cell line has been officially recognized by the United States Patent and Trademark Office as important for the production of human vaccines, making the process more efficient and cost effective. This proprietary method of developing viral vaccines is also master filed at the FDA's Center for Biologics Evaluation and Research, making it a valuable asset to Novavax since the method will be available for licensure to other companies conducting research in this arena."

Novavax is a biopharmaceutical drug delivery company engaged in the research and development of differentiated drug products for large and growing markets. The company is applying its proprietary lipid vesicle encapsulation technologies including Novasome lipid vesicles and micellar nanoparticles to develop product candidates for the topical and oral delivery of generic and non-generic drugs, peptides, proteins and oligonucleotides. The company's Novasome technology is also being developed as an adjuvant delivery system for enhanced vaccine efficacy. Novavax has several product candidates in pre-clinical and human clinical trials, including ESTRASORB, a topical cream for estrogen replacement therapy which has entered Phase III clinical testing. Novavax's biomedical services division is engaged in contract research and development and Phase I/II vaccine manufacturing of human vaccines for government laboratories and other vaccine companies.
COPYRIGHT 2000 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Novavax receives important patent covering the production of viral vaccines in a proprietary cell line.
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Mar 1, 2000
Previous Article:Chiron granted hepatitis C patent.
Next Article:Reprogenesis acquires exclusive license to Children's Hospital/Harvard/MIT organ regeneration technology and product for bladder reconstruction.

Related Articles
Novavax and the National Institutes of Health awarded key patents on hepatitis E vaccine.
Vical announces issuance of key naked DNA vaccine patent.
Avigen granted gene therapy patent for intravenous delivery of Aav vectors.
Vical obtains angiogenesis patent.
Galenica awarded patent for chemically modified immune enhancing agents.
Vical announces issuance of patent for gene-based cancer therapy.
Transkaryotic announces victory in Genzyme patent litigation.
Cell Genesys issued patent for oncolytic virus.
Aastrom Biosciences receives culture device European patent.
Novavax licenses Wyeth's virus-like particle technology.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters